Literature DB >> 11454714

Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis.

J Y Ljubimova1, A J Lakhter, A Loksh, W H Yong, M S Riedinger, J H Miner, L M Sorokin, A V Ljubimov, K L Black.   

Abstract

Differential gene expression in tumors often involves growth factors and extracellular matrix/basement membrane components. Here, 11,000- gene microarray was used to identify gene expression profiles in brain tumors including high-grade gliomas [glioblastoma multiforme (GBM) and anaplastic astrocytoma], low-grade astrocytomas, or benign extra-axial brain tumors (meningioma) in comparison with normal brain tissue. Histologically normal tissues adjacent to GBMs were also studied. All GBMs studied overexpressed 14 known genes compared with normal human brain tissue. Overexpressed genes belonged to two broad groups: (a) growth factor-related genes; and (b) structural/extracellular matrix-related genes. For most of these 14 genes, expression levels were lower in low-grade astrocytoma than in GBM and were barely detectable in normal brain. Despite normal-appearing histology, gene expression patterns of tissues immediately adjacent to GBM were similar to those of their respective primary GBMs. Two genes were consistently up-regulated in both high-grade and low-grade gliomas, as well as in histologically normal tissues adjacent to GBMs. These genes coded for the epidermal growth factor receptor (previously reported to be overexpressed in gliomas) and for the alpha4 chain of laminin, a major blood vessel basement membrane component. Changes in expression of this laminin chain have not been previously associated with malignant tumors. Overexpression of laminin alpha4 chain in GBM and astrocytoma grade II by gene microarray analysis was confirmed by semiquantitive reverse transcription-PCR and immunohistochemistry. Importantly, an alpha4 chain-containing laminin isoform, laminin-8 (alpha4beta1gamma1), was expressed mainly in blood vessel walls of GBMs and histologically normal tissues adjacent to GBMs, whereas another alpha4 chain-containing laminin isoform, laminin-9 (alpha4beta2gamma1), was expressed mainly in blood vessel walls of low-grade tumors and normal brain. GBMs that overexpressed laminin-8 had a shorter mean time to tumor recurrence (4.3 months) than GBMs with overexpression of laminin-9 (9.7 months, P = 0.0007). Up-regulation of alpha4 chain-containing laminins could be important for the development of glioma-induced neovascularization and glial tumor progression. Overexpression of laminin-8 may be predictive of glioma recurrence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454714

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Inhibition of brain tumor growth by intravenous poly (β-L-malic acid) nanobioconjugate with pH-dependent drug release [corrected].

Authors:  Hui Ding; Satoshi Inoue; Alexander V Ljubimov; Rameshwar Patil; Jose Portilla-Arias; Jinwei Hu; Bindu Konda; Kolja A Wawrowsky; Manabu Fujita; Natalya Karabalin; Takako Sasaki; Keith L Black; Eggehard Holler; Julia Y Ljubimova
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

2.  Stripe-like increase of rCBV beyond the visible border of glioblastomas: site of tumor infiltration growing after neurosurgery.

Authors:  Stella Blasel; Kea Franz; Hanns Ackermann; Stefan Weidauer; Friedhelm Zanella; Elke Hattingen
Journal:  J Neurooncol       Date:  2010-10-07       Impact factor: 4.130

3.  Mining microarrays for metabolic meaning: nutritional regulation of hypothalamic gene expression.

Authors:  Charles V Mobbs; Kelvin Yen; Jason Mastaitis; Ha Nguyen; Elizabeth Watson; Elisa Wurmbach; Stuart C Sealfon; Andrew Brooks; Stephen R J Salton
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

Review 4.  Laminin isoforms in development and disease.

Authors:  Susanne Schéele; Alexander Nyström; Madeleine Durbeej; Jan F Talts; Marja Ekblom; Peter Ekblom
Journal:  J Mol Med (Berl)       Date:  2007-04-11       Impact factor: 4.599

5.  Proteinase and growth factor alterations revealed by gene microarray analysis of human diabetic corneas.

Authors:  Mehrnoosh Saghizadeh; Andrei A Kramerov; Jian Tajbakhsh; Annette M Aoki; Charles Wang; Ning-Ning Chai; Julia Y Ljubimova; Takako Sasaki; Gabriel Sosne; Marc R J Carlson; Stanley F Nelson; Alexander V Ljubimov
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-10       Impact factor: 4.799

Review 6.  Changes in laminin isoforms associated with brain tumor invasion and angiogenesis.

Authors:  Julia Y Ljubimova; Manabu Fujita; Natalya M Khazenzon; Alexander V Ljubimov; Keith L Black
Journal:  Front Biosci       Date:  2006-01-01

7.  Gene expression profiling-based identification of CD28 and PI3K as new biomarkers for chronic graft-versus-host disease.

Authors:  Peilong Lai; Jianyu Weng; Zesheng Lu; Rong Guo; Chenwei Luo; Suijing Wu; Wei Ling; Suxia Geng; Xin Du
Journal:  DNA Cell Biol       Date:  2011-06-17       Impact factor: 3.311

8.  Polycefin, a new prototype of a multifunctional nanoconjugate based on poly(beta-L-malic acid) for drug delivery.

Authors:  Bong-Seop Lee; Manabu Fujita; Natalya M Khazenzon; Kolja A Wawrowsky; Sebastian Wachsmann-Hogiu; Daniel L Farkas; Keith L Black; Julia Y Ljubimova; Eggehard Holler
Journal:  Bioconjug Chem       Date:  2006 Mar-Apr       Impact factor: 4.774

9.  Senescence-induced alterations of laminin chain expression modulate tumorigenicity of prostate cancer cells.

Authors:  Cynthia C T Sprenger; Rolf H Drivdahl; Lillie B Woodke; Daniel Eyman; May J Reed; William G Carter; Stephen R Plymate
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

10.  Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age.

Authors:  Andrey Korshunov; Kai Neben; Gunnar Wrobel; Bjoern Tews; Axel Benner; Meinhard Hahn; Andrey Golanov; Peter Lichter
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.